132 related articles for article (PubMed ID: 24843604)
21. Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway.
Samikannu B; Chen C; Lingwal N; Padmasekar M; Engel FB; Linn T
PLoS One; 2013; 8(12):e82639. PubMed ID: 24349326
[TBL] [Abstract][Full Text] [Related]
22. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
[TBL] [Abstract][Full Text] [Related]
23. Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice.
Maki T; Gottschalk R; Monaco AP
Transplantation; 2002 Dec; 74(12):1684-6. PubMed ID: 12499880
[TBL] [Abstract][Full Text] [Related]
24. One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Aston-Mourney K; Subramanian SL; Zraika S; Samarasekera T; Meier DT; Goldstein LC; Hull RL
Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E475-84. PubMed ID: 23736544
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the Effects of Mitiglinide and Glibenclamide Administered in Combination with the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin in Rats with Streptozotocin-Nicotinamide-Induced Type 2 Diabetes.
Akahane K; Ojima K; Yokoyama A; Inoue T; Kiguchi S; Tatemichi S; Takeda H; Kobayashi M
Drug Res (Stuttg); 2017 Jul; 67(7):396-403. PubMed ID: 28486736
[TBL] [Abstract][Full Text] [Related]
26. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
27. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
28. Effect of FTY720 on some physiological indexes of Non-Obese Diabetic (NOD) Mice.
Chen X; Ye S; Zhang S; Li J; Zhu H; Zheng G; Lu Y; Wan H
Int J Mol Sci; 2012; 13(5):6129-37. PubMed ID: 22754354
[TBL] [Abstract][Full Text] [Related]
29. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
[TBL] [Abstract][Full Text] [Related]
30. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
Dobrian AD; Ma Q; Lindsay JW; Leone KA; Ma K; Coben J; Galkina EV; Nadler JL
Am J Physiol Endocrinol Metab; 2011 Feb; 300(2):E410-21. PubMed ID: 21081706
[TBL] [Abstract][Full Text] [Related]
31. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
32. Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.
Kashiwagi A; Kadowaki T; Tajima N; Nonaka K; Taniguchi T; Nishii M; Ferreira JC; Amatruda JM
J Diabetes Investig; 2011 Oct; 2(5):381-90. PubMed ID: 24843518
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
34. Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells.
Liang J; Leung KK; Lam SY; Leung PS
Diabetes Obes Metab; 2012 Sep; 14(9):842-51. PubMed ID: 22519909
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
36. Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1β and IL-12 in NOD mice.
He X; Li W; Xie Y; Zhao Y
Int Immunopharmacol; 2020 Nov; 88():106945. PubMed ID: 33182020
[TBL] [Abstract][Full Text] [Related]
37. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
Chwieduk CM
Drugs; 2011 Feb; 71(3):349-61. PubMed ID: 21319871
[TBL] [Abstract][Full Text] [Related]
38. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME
Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958
[TBL] [Abstract][Full Text] [Related]
39. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.
Kim SJ; Nian C; McIntosh CH
Diabetes; 2010 Jul; 59(7):1739-50. PubMed ID: 20368408
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
Pasquel FJ; Gianchandani R; Rubin DJ; Dungan KM; Anzola I; Gomez PC; Peng L; Hodish I; Bodnar T; Wesorick D; Balakrishnan V; Osei K; Umpierrez GE
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):125-133. PubMed ID: 27964837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
